-
The price of the shares of this company collapses after the decision of Nasdaq.
-
The decision has nothing to do with the accumulation of BNB, but with a regulatory breach.
Windtree Therapeutics, Inc., Biopharmaceutical Company based in Warrington, Pennsylvania, announced that their shares will stop contributing in the Nasdaq capital market as of August 21, 2025.
The decision occurs after the notification of the US stock market itself, which determined exclusion due to the repeated breach of contribution standard 5550 (a) (2), related to the minimum price of the shares.
It is worth clarifying that The expulsion is not related to the business of this company that – as Cryptonoticias reported it – is in transition to focus on bnb accumulation and stakingcryptocurrency that was created by Exchange Binance.
Consequently to the decision of Nasdaq, The ordinary shares of Windreeidentified with the wint symbol, They will be negotiated in the extraburstyl market (OTC, for its acronym in English), specifically on the OTCID platform, for which the company already submitted a request. However, the company warned that there is no guarantee that such application is approved.
After these novelties, the price of Wint fell more than 70% in a matter of minutes, as seen in the following tradingview graph:
The firm stressed that the change of contribution platform will not affect its operations or its business model. The statement, signed by the president and executive director, Jed Latkin, also included a precautionary statement on future projections. The company stressed that, although an orderly transition to the OTC market, external and internal factors could influence the results and acceptance of its titles in that market.
The suspension of the price in Nasdaq and the transfer to the OTC market mark a new chapter for Windree Therapeutics, which must now face the visibility and liquidity challenges that involve operating outside a larger stock market.